Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy for chronic hepatitis C. Present status.

M Rizzetto1

  • 1Università degli Studi--Torino, Cattedra di Gastroenterologia, Azienda Ospedaliera S. Giovanni Battista, Divisione di Gastroenterologia.

Minerva Gastroenterologica E Dietologica
|February 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of hepatitis D: an unmet medical need.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020
Same author

Letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D - authors' reply.

Alimentary pharmacology & therapeutics·2017
Same author

HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response.

Alimentary pharmacology & therapeutics·2016
Same author

Hepatorenal syndrome after treatment of visceral leishmaniasis requiring terlipressin therapy.

Minerva gastroenterologica e dietologica·2015
Same author

Antiviral treatment discontinuation among hepatitis C-infected individuals with thrombocytopenia.

Journal of viral hepatitis·2015
Same author

Letter: renal effects of tenofovir in adefovir dipivoxil-experienced HBV patients.

Alimentary pharmacology & therapeutics·2014
Same journal

Hepatic steatosis integrated approach: nutritional guidelines and joined nutraceutical administration.

Minerva gastroenterologica e dietologica·2021
Same journal

Diagnostic accuracy of computerized tomography (CT) angiography in detecting non-variceal gastrointestinal bleeding (NVGIB): a sistematic review.

Minerva gastroenterologica e dietologica·2020
Same journal

Helicobacter pylori and non-alcoholic fatty liver disease.

Minerva gastroenterologica e dietologica·2020
Same journal

Hypertriglyceridemic pancreatitis.

Minerva gastroenterologica e dietologica·2020
Same journal

Effectiveness of percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis.

Minerva gastroenterologica e dietologica·2020
Same journal

Noninvasive diagnosis of fibrosis in non-alcoholic fatty liver disease: diagnostic accuracy of different scores.

Minerva gastroenterologica e dietologica·2020
See all related articles

Interferon (IFN) therapy for chronic hepatitis C shows limited long-term benefit. Combining IFN with ribavirin significantly increases response rates compared to IFN monotherapy alone.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Interferon (IFN) is the sole approved worldwide treatment for chronic hepatitis C.
  • While extrapolations suggest IFN may favorably alter disease progression, long-term benefits remain unproven.
  • Limited efficacy of IFN monotherapy has driven the development of alternative and complementary therapies.

Purpose of the Study:

  • To evaluate the efficacy of novel therapeutic strategies for chronic hepatitis C.
  • To compare the outcomes of IFN monotherapy with combination therapies.
  • To identify optimal treatment approaches for different patient populations.

Main Methods:

  • Review of existing meta-analyses and clinical trial data on chronic hepatitis C treatments.
  • Comparative analysis of response rates between IFN monotherapy and combination therapies (IFN with ribavirin).

Related Experiment Videos

  • Assessment of treatment efficacy in IFN-naive patients, IFN relapsers, and non-responders.

    • Main Results:

    • Attempts to improve alpha-IFN monotherapy through new formulations or dosage adjustments yielded no significant benefit over classical protocols.
    • Combination therapy with interferon and ribavirin demonstrated a threefold increase in overall response rates compared to IFN monotherapy.
    • Combination therapy is effective for treatment-naive patients and those who relapse after IFN treatment.

    Conclusions:

    • Combination therapy represents a significant therapeutic advancement over IFN monotherapy for chronic hepatitis C.
    • Interferon and ribavirin combination therapy is the current treatment of choice for most chronic hepatitis C patients.
    • This combination therapy is not effective in patients who have previously not responded to interferon treatment.